Previous Article | Next Article 
Journal of Virology, November 2000, p. 10034-10040, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Severe Murine Lung Immunopathology Elicited by the Pathogenic
Equine Herpesvirus 1 Strain RacL11 Correlates with Early Production
of Macrophage Inflammatory Proteins 1
, 1
, and 2 and Tumor
Necrosis Factor Alpha
Patrick M.
Smith,1
Yunfei
Zhang,1
Warren D.
Grafton,2
Stephen R.
Jennings,1 and
Dennis
J.
O'Callaghan1,*
Department of Microbiology and
Immunology1 and Department of
Pathology,2 Louisiana State University
Health Sciences Center, Shreveport, Louisiana 71130
Received 16 March 2000/Accepted 9 August 2000
 |
ABSTRACT |
The CBA mouse model was used to investigate the immunopathology
induced in the lung by the pathogenic equine herpesvirus 1 (EHV-1)
strain RacL11 in comparison to infection with the attenuated vaccine
candidate strain KyA. Intranasal infection with KyA resulted in almost
no inflammatory infiltration in the lung. In contrast, infection with
the pathogenic RacL11 strain induced a severe alveolar and interstitial
inflammation, consisting primarily of lymphocytes, macrophages, and
neutrophils. Infection with either EHV-1 strain resulted in the
accumulation of similar numbers and ratios of CD4 and CD8 T lymphocytes
in the lung and bronchoalveolar lavage (BAL) fluid. Further analysis of
these T-cell populations revealed identical EHV-1-specific cytotoxic
T-lymphocyte responses. RNase protection analysis of RNA isolated from
the BAL fluid of RacL11-infected mice on day 3 postinfection revealed
much higher levels of RNA specific for macrophage inflammatory protein
1
(MIP-1
), MIP-1
, and MIP-2 than were observed for
KyA-infected mice. Furthermore, significantly higher levels of
transcripts specific for tumor necrosis factor alpha were induced on
day 3 postinfection with RacL11 compared with KyA. These findings
suggest that the early production of proinflammatory beta chemokines
plays a major role in the severe, most often lethal, respiratory
inflammatory response induced by the pathogenic EHV-1 strain RacL11.
 |
INTRODUCTION |
Naturally occurring mucosal
infection of the horse with equine herpesvirus 1 (EHV-1) typically
results in respiratory distress, abortogenic disease, and, albeit
rarely, severe neurological sequelae (5, 13, 24, 30, 31,
32). By far the most devastating outcome of EHV-1 infection
of the horse is the induction of abortion in pregnant mares,
which has a severe economic impact on the equine industry.
EHV-1-induced abortion in pregnant mares requires a sequential
infection of the respiratory epithelium, followed by infection of
mononuclear cells and T cells, resulting in a cell-associated viremia
and subsequent infection of endothelial cells within the endometrial
vasculature (6, 10, 40). Currently, there are no available
EHV-1 vaccines that elicit long-term immunity and protection in the
horse (11, 12, 22).
The mouse model of EHV-1 infection was originally established in
various mouse strains (2, 7). We recently adapted this model
to CBA (H-2k) mice to allow characterization of
the primary and memory EHV-1-specific cytotoxic T-lymphocyte (CTL)
responses to the attenuated vaccine candidate EHV-1 strain KyA
(15, 28, 41). In these studies it was reported that KyA
afforded protection in the mouse and the horse against subsequent
infection with the highly pathogenic EHV-1. It was observed that KyA
infection of CBA mice resulted in no clinical signs of infection. In
contrast, infection of CBA mice with the pathogenic RacL11 strain
resulted in severe weight loss, ruffled fur, huddling behavior, and
eventually death between days 6 and 8 postinfection (41,
48).
Those observations strongly suggested a fundamental difference between
these two EHV-1 strains in growth potential in vivo and/or in the
host-virus interaction. Measurement of virus levels in the lungs on
days 2 through 6 postinfection indicated that the pathogenic RacL11
strain was cleared from the lung tissue with kinetics identical to
those observed following infection with the attenuated KyA strain.
Infection with either EHV-1 strain resulted in peak viral titers on day
2 postinfection, and infectious virus was completely eliminated from
the lung tissue by day 6 (40). Since these mice succumbed to
RacL11 infection on days 6 to 8 postinfection, it was speculated
that death was likely the result of the host interaction with
EHV-1 RacL11, and not the result of inability to clear this EHV-1
strain from the lung. A clear understanding of the immune
mechanisms that constitute a protective "appropriate" response
versus a potentially damaging "inappropriate" response and the
identification of viral components responsible for eliciting those
responses are imperative for the development of an immunoprophylactic vaccine.
In the present study, we examined the acquired immune response in the
infected lung following infection with EHV-1 KyA or RacL11 and the
subsequent immunopathology as a result of that response. We found that
intranasal (i.n.) infection with the pathogenic RacL11 strain results
in a severe inflammatory infiltration involving the majority of the
lung tissue, a finding not observed following KyA infection. Lung
sections taken from RacL11-infected mice revealed a massive cellular
consolidation of the lung, consisting primarily of lymphocytes,
macrophages, and neutrophils. Lung sections from KyA-infected mice were
almost completely clear of inflammatory infiltration, closely
resembling sections taken from mock-infected mice. These results
suggest that, while the immune response elicited by KyA is protective,
the response to RacL11 is damaging and results in the death of the
animal. Immune mechanisms potentially playing a role in this
inappropriate response and leading to severe immunopathology of the
lung are characterized and discussed.
 |
MATERIALS AND METHODS |
Virus and cell culture.
EHV-1 KyA and RacL11 viral stocks
used for i.n. infection of mice were propagated on L2 mouse fibroblast
monolayers. Titers of both virus strains were determined by standard
plaque titration on RK monolayers as described previously (37, 41,
48, 49). Cells were maintained at 37°C in Eagle's minimal
essential medium supplemented with penicillin (100 U per ml),
streptomycin (100 µg per ml), nonessential amino acids, and 5% fetal
calf serum (FCS).
Mice.
Female CBA mice, 3 to 6 weeks of age, were obtained
from Harlan Sprague Dawley (Indianapolis, Ind.). Mice were maintained in the Animal Resource Facility of the Louisiana State University Health Sciences Center, Shreveport, in filter-topped cages. This facility is certified by the Association for Assessment and
Accreditation of Laboratory Animal Care International, and all
procedures were approved by the University Animal Care Committee. All
mice were rested a minimum of 1 week prior to use. In all experiments,
mouse groups consisted of at least five mice each. CTL assays and RNase protection analysis were performed using pooled cells isolated from
groups of five mice. All experiments were performed a minimum of three times.
Histopathology.
Representative lungs from groups of infected
(i.n., with 2 × 106 PFU of KyA or RacL11) mice
consisting of five mice per group were infused in vivo with 1 ml of
10% buffered formalin, removed, and placed in 10% buffered formalin.
Paraffin sections were cut, and individual sections were stained with
hematoxylin and eosin.
Identification and quantitation of cells isolated from the BAL
fluid.
Mice were infected i.n. with 2 × 106 PFU
of KyA or RacL11, and the bronchoalveolar lavage (BAL) fluid was
recovered on day 5 postinfection as follows. Mice were sacrificed by
halothane inhalation, and the pleural cavity was exposed. The trachea
was cut just below the larynx, and a smooth-tipped 20-gauge needle was
inserted into the trachea. The needle was secured in place by tying
with waxed dental floss. BAL fluid was obtained by using a 1-ml syringe
to infuse 1-ml aliquots of phosphate-buffered saline (PBS) in and out
of the lungs five times for a total of 5 ml. Cells isolated from the
BAL fluid were then air dried onto a glass slide, fixed for 5 min in
methanol, stained for 20 min with Giemsa stain, and rinsed with
double-distilled water. Cell types were identified by standard
morphological evaluation under light microscopy, and percentages of
each cell type were determined by a differential count of at least 200 stained cells per sample. The data are presented as mean percentages
over a range of five separate experiments.
Infection and assessment of CTL activity.
CBA mice were
anesthetized with halothane (Sigma Chemical Co, St. Louis, Mo.) and
inoculated i.n. with 2 × 106 PFU of EHV-1 KyA or
RacL11 in an inoculum volume of 50 µl. To assess primary CTL activity
in the lung at 5 days postinfection, lymphocytes were isolated from the
lung tissues as follows. The lungs were removed in the absence of the
draining mediastinal lymph nodes (LN), and the tissue was minced with
scissors, pressed through a 60-gauge mesh screen, and digested for 90 min with collagenase (250 U per ml) and DNase I (50 U per ml). The
released lymphocytes were briefly exposed at 37°C to Tris-buffered
0.83% NH4Cl to lyse erythrocytes and then cultured for 3 days at 37°C under 5% CO2 in 12-well plates at a
concentration of 107 cells per well in a total volume of 4 ml of complete RPMI 1640 (Sigma) containing 5% FCS, 20 µM
-mercaptoethanol, 20 mM HEPES, 2 mM L-glutamine, and
antibiotics. Cytolytic activity was assessed in a standard 4-h
51Cr release assay in 96-well V-bottom plates (Nunc,
Roskilde, Denmark) against a range of effector-to-target ratios,
utilizing 104 51Cr-labeled, KyA-infected or mock-infected
murine L2 fibroblasts (H-2k) as previously
described (40). The percentage of specific lysis was
determined by using the formula (A
B)/(C
B) × 100, where A is the amount of 51Cr released by target cells
incubated with effector cells (experimental release), B is the amount
of 51Cr released from targets incubated in medium alone
(spontaneous release), and C is the amount of 51Cr released
from targets incubated in 3% acetic acid (maximum release). Each
effector-to-target ratio was assayed in triplicate. The spontaneous
release never exceeded 20%, and the variability among the
specific-lysis values of triplicate cultures did not exceed 5%.
Flow cytometric analysis.
Lymphocytes were isolated from
lungs 5 days postinfection by pressing through a 60-gauge screen and
digestion with DNase-collagenase as described above. Lymphocytes were
isolated from the BAL fluid on day 5 postinfection as described above.
Following isolation, the resulting lymphocytes were stained with
phycoerythrin (PE)-conjugated monoclonal antibodies specific for murine
CD4 or CD8 (PharMingen, San Diego, Calif.) and a fluorescein
isothiocyanate (FITC)-conjugated monoclonal antibody specific for
murine CD3
(PharMingen). Stained cells were analyzed on a
FACScaliber flow cytometer-analyzer (Becton Dickinson, San Jose,
Calif.). Flow cytometric and off-line data analyses were provided by
the Core Facility for Flow Cytometry, Louisiana State University Health
Sciences Center, Shreveport.
Isolation of mRNA and RNase protection analysis.
BAL fluid
was obtained 3 days post-i.n. infection with either KyA or RacL11 as
described above. RNA was obtained from the resulting cells by using the
TRIZOL reagent (Life Technologies, Grand Island, N.Y.) according to the
manufacturer's protocol.
RNase protection assays were performed by using the
32P-based RiboQuant Multi-Probe RNase protection assay
system (PharMingen) according to the manufacturer's protocol.
Protected RNA species and appropriate standards were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
using 5% acrylamide gels, which were then blotted onto filter paper,
dried, and exposed to film. The resulting film was scanned using the UV
Transilluminator 2000 (Bio-Rad, Hercules, Calif.), and bands were
quantitated by using the Quantity One program (Bio-Rad) according to
the manufacturer's protocol.
 |
RESULTS |
Flow cytometric analysis of T cells isolated from the lung.
The striking differences between the outcomes of infection with KyA
versus RacL11 strongly suggested that a fundamental difference exists
between the ways these two strains grow in vivo and/or between the
immune responses elicited to them. The former was ruled out by our
previous demonstration that infectious RacL11 and KyA are completely
cleared from the lung tissue by day 6 postinfection with identical
kinetics (41). These results and the observation that the
mice exhibited labored breathing before succumbing to infection
suggested that the fatality observed following RacL11 infection might
be the result of severe immunopathology in the lung. Flow cytometric
analysis revealed that CD4 and CD8 T cells isolated from the entire
lung were present in almost identical CD4/CD8 ratios of approximately
2:1 at 5 days following infection with either KyA or pathogenic RacL11
(Fig. 1). Interestingly, in the BAL fluid
on day 5 postinfection, CD8 T cells were the predominant lymphocyte
population, and a CD4/CD8 ratio of approximately 0.6:1 was observed in
both RacL11- and KyA-infected mice (Fig. 1). Although T cells were
present in the lungs of KyA- and RacL11-infected mice in comparable
numbers and ratios, the total number of cells isolated from
RacL11-infected lungs, most likely infiltrating monocytes and
granulocytes, was generally 5- to 10-fold greater (data not shown).
These results suggested a much more vigorous inflammatory infiltration
into the lung in response to infection with RacL11.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 1.
Flow cytometric analysis of lymphocytes isolated from
EHV-1-infected lungs on day 5 postinfection. CBA mice were infected
i.n. with 2 × 106 PFU of EHV-1 KyA or RacL11. At 5 days postinfection, the lungs were removed, and lymphocytes were
isolated by collagenase-DNase digestion as described in Materials and
Methods. BAL fluid was obtained at day 5 postinfection as described in
Materials and Methods. The resulting lymphocytes were then double
stained with FITC-CD3 and PE-CD4 or PE-CD8 and were analyzed by flow
cytometric analysis.
|
|
Assessment of inflammatory infiltration in the infected lung.
Macroscopic observation of KyA- and RacL11-infected lungs revealed a
much more extensive inflammatory response following RacL11 infection
(data not shown). The consolidation involved more than 90% of the
total lung tissue compared to that observed following infection with
KyA. Although inflammation was present in KyA-infected lungs compared
to uninfected lungs, it encompassed only approximately 10 to 20% of
the total lung. Histological analysis of infected lungs confirmed these
observations. Figure 2A and B show the
typical appearance of uninfected CBA lung tissue. On day 5 postinfection, KyA-infected lungs exhibited mild perivascular and
peribronchial inflammation, consisting mostly of lymphocytes, with
little or no infiltration into the alveolar spaces (Fig. 2C and D). The inflammatory cells infiltrating the RacL11-infected lung also appeared
to be primarily lymphocytes (Fig. 2E and F). However, the lesion
present in the RacL11-infected lung appeared much more severe,
exhibiting diffuse alveolar damage (DAD) with alveolar edema and
diffuse interstitial infiltration (Fig. 2E). Further, leakage of
protein-rich fluid from the alveolar capillaries into the alveoli
resulted in the formation of hyaline membranes lining the alveolar
walls (Fig. 2F). Morphological examination and quantitation by light
microscopy of cells isolated from the BAL fluid revealed that the BAL
fluid of RacL11-infected mice consisted of lymphocytes, macrophages,
and neutrophils (Table 1). In contrast,
the infiltrating cells isolated from the BAL fluid of KyA-infected mice
consisted of lymphocytes and macrophages; no neutrophils were detected
(Table 1). We have observed previously that consolidation within the RacL11-infected lung was most severe when viral titers were at their
lowest (days 5 and 6 postinfection). Taken together, these results
suggested that fatality following RacL11 infection was likely due to
severe DAD and was independent of levels of infectious virus
(41).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 2.
Histological sections of infected lungs at 5 days
postinfection. Lungs were infused with 10% buffered formalin and
removed 5 days following mock infection (A and B) or i.n. infection
with 2 × 106 PFU of KyA (C and D) or RacL11 (E and
F). Paraffin sections were cut and stained with hematoxylin and
eosin.
|
|
Analysis of cytolytic activity of lymphocytes isolated from
infected lungs.
The severe inflammatory response in the lungs of
RacL11-infected mice, present in the absence of infectious RacL11,
suggested that an immunopathological response elicited by this
pathogenic EHV-1 strain and likely mediated by T lymphocytes results in
fatality. Although the results in Fig. 1 clearly show a similar
presence of CD4 and CD8 T cells within the lungs and BAL fluid of mice infected with either KyA or RacL11, they reveal nothing regarding the
function of these lymphocytes. We have previously characterized the
primary and memory CTL responses elicited by KyA in the draining LN and
spleen, respectively (41). To date, however, there is no
information regarding CTL activity directed to the RacL11 EHV-1 strain.
Furthermore, primary CTL activity isolated from the infected lung and
directed against either KyA or RacL11 has not been demonstrated. When
lymphocytes were isolated by enzymatic digestion from the entire lung,
cultured for 3 days in vitro, and tested against EHV-1-infected
targets, the primary CTL responses elicited by KyA and RacL11 were
identical (Fig. 3). Further, when the
cytolytic activity of lymphocytes isolated from the BAL fluid at 5 days postinfection was assessed, the primary EHV-1-specific CTL responses were also very similar. The percent specific lysis at an
effector-to-target ratio of 30:1 was 32 and 36% for the BAL fluid from
KyA- and RacL11-infected mice, respectively (data not shown). In a
previous report (41), it was observed that KyA elicited a
vigorous primary CTL response in the draining mediastinal LN but not in
the draining cervical LN, even though the cervical LN drains the nasal
turbinates, an important site for initial EHV-1 replication
(7). Identical findings were observed following infection
with the pathogenic RacL11 strain (data not shown). Taken together,
these results indicate that, by all parameters tested, the primary
RacL11-specific CTL response in the draining LN and lung is identical
to that observed following infection with the attenuated EHV-1 strain KyA.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Cytolytic activity isolated from the lungs of KyA- and
RacL11-infected mice. CBA mice were infected i.n. with 2 × 106 PFU of KyA or RacL11. On day 5 postinfection, the lungs
were removed and lymphocytes were isolated by collagenase-DNase
digestion as previously described. The resulting lymphocytes were
cultured in complete RPMI for 3 days at 37°C in 5% CO2
as described in Materials and Methods. Cytolytic activity was measured
in a standard 4-h 51Cr release assay using mock-infected
( ) or KyA-infected ( ) mouse fibroblasts as targets. Each
effector-to-target (E:T) ratio was assayed in triplicate. The
spontaneous release never exceeded 20%, and the variability among the
specific-lysis values of triplicate cultures did not exceed 5%.
|
|
Analysis of cytokine transcripts in the infected lung.
The
identical kinetics of viral clearance and the striking similarity of
the primary CTL responses following RacL11 infection and KyA infection
suggest that the massive inflammatory response within the
RacL11-infected lung may reflect a difference in the profile of
cytokines elicited by pathogenic versus attenuated EHV-1. RNase
protection assays were performed to identify differences between the
profiles of specific proinflammatory cytokines elicited by these two
biologically distinct EHV-1 strains. RNase protection assays analyzing
RNA isolated from the entire lung on days 3 and 5 postinfection
revealed equivalent amounts of transcripts specific for interleukin 10 (IL-10) and the proinflammatory cytokines IL-15, IL-6, and gamma
interferon in KyA- and RacL11-infected lungs (data not shown). However,
when RNA isolated from BAL fluid on days 3 and 5 was analyzed, much
higher levels of transcripts specific for the proinflammatory cytokine
tumor necrosis factor alpha (TNF-
) (Fig.
4A) and the beta chemokines macrophage
inflammatory protein 1
(MIP-1
), MIP-1
, and MIP-2 (Fig. 4B)
were detected on day 3 for RacL11-infected mice. Quantitation of
results from four separate experiments demonstrated a consistent
upregulation of MIP-1
, MIP-1
, and MIP-2 transcripts relative to
the housekeeping gene L32 in EHV-1 RacL11-infected lungs (Table
2). In all four experiments, the levels
of MIP transcripts from RacL11-infected mice were above the levels of
L32 transcripts. In contrast, the levels of transcripts of all three
MIP chemokines from KyA-infected lungs were consistently below the
levels of L32 transcripts. MIP transcript levels in KyA- and
RacL11-infected mice, calculated as percentages of L32 transcript
levels, were compared, and the levels of MIP transcripts in
RacL11-infected mice ranged from ~2- to ~7-fold greater than those
in KyA-infected mice (Table 2). Interestingly, the levels of MIP-1
,
MIP-1
, and MIP-2 transcripts isolated from the BAL fluid of
RacL11-infected mice decreased by day 5 postinfection, while the levels
in KyA-infected mice remained relatively unchanged (Fig. 4B). These
results suggest that a rapid and vigorous production of these
proinflammatory chemokines plays a major role in recruiting the massive
inflammatory infiltration present in RacL11-infected lungs.

View larger version (115K):
[in this window]
[in a new window]
|
FIG. 4.
Detection of cytokine mRNA by RNase protection analysis.
CBA mice were infected i.n. with 2 × 106 PFU of KyA
or RacL11. On days 3 and 5 postinfection the mice were sacrificed, and
BAL fluid was obtained as described in Materials and Methods. Total RNA
was isolated from the BAL fluid by using the TRIZOL reagent (Life
Technologies) as described in Materials and Methods.
32P-labeled probes specific for various cytokine mRNA
species were generated by in vitro transcription using the probe sets
mCK-2b (A) and mCK-5 (B) (RNase protection assay kit; PharMingen).
RNase protection analysis was carried out according to the
manufacturer's protocol. Control lanes included the labeled probes
alone, pooled mouse RNA (+), and yeast tRNA ( ).
|
|
 |
DISCUSSION |
Natural infections of horses with EHV-1 are associated with
distinctive immunopathology of the upper respiratory tract and pathognomonic clinical signs (5). However, infection with
the EHV-1 vaccine candidate strain KyA exhibits none of these signs and
protects equines against subsequent infection with pathogenic, clinical
isolates of EHV-1 (28). This difference between the host
responses to the two viral strains suggested that the respiratory tract
disease was due to immunopathological changes induced by clinical
isolates rather than to differences between the immune responses to the
two strains.
In CBA (H-2k) mice, clinical signs reminiscent
of those in the equine are observed in response to infection with the
pathogenic strain RacL11. However, the pathogenic strain RacL11 and the
attenuated strain KyA reach similar levels of infectious progeny in the
infected lung (41) and induce similar CD8+
T-cell responses (this study). Importantly, the two virus strains are
cleared with identical kinetics, indicating that the severe clinical
signs and fatality following RacL11 infection are not due specifically
to viral load, but instead likely represent an immunopathological
response by the host to the pathogenic strain. Further, both strains
induce the infiltration of similar numbers and ratios of CD4 and CD8 T
cells and induce identical EHV-1-specific CTL responses within the
lung, BAL fluid, and draining LN. Therefore, the clinical outcome of
RacL11 infection is not due to virus load or to the failure of the
virus to induce a humoral (48) or cell-mediated immune
response (41). The intense inflammatory response and DAD
associated with RacL11 infection suggest that this strain has the
ability to induce damaging cytokine species within the lung.
RNase protection analysis of transcripts isolated from the entire lung,
either by physical grinding or by enzymatic digestion, revealed no
obvious differences in the cytokines produced in the lung following
infection with either strain (data not shown). However, when mRNA was
isolated from the BAL fluid, the levels of MIP-1
, MIP-1
, MIP-2,
and TNF-
transcripts on day 3 postinfection were much greater in
response to RacL11 than to KyA. Early studies reported proinflammatory
properties associated with these chemokines (16, 17, 39).
Subsequent studies have implicated MIP-1
and MIP-1
in a variety
of inflammatory diseases, including inflammatory muscle disease
(1), herpes stromal keratitis (41), alcoholic hepatitis (3), and pulmonary inflammation (18,
26). Similarly, an important role for MIP-2 in pulmonary sepsis
and interstitial lung disease has been demonstrated (18, 23,
45). The chemotactic properties of MIP-1
, MIP-1
, and MIP-2
for neutrophils (16, 39, 44) and monocytes (18,
43) correlate with the presence of both monocytes and neutrophils
in the BAL fluid isolated from RacL11-infected lungs at 5 days
postinfection. Interestingly, the levels of MIP-1
, MIP-1
, and
MIP-2 transcripts are actually much lower in RacL11-infected lungs 5 days postinfection than in KyA-infected lungs. The downregulation of
chemokine production by day 5 occurs when cellular infiltration is most
severe and likely reflects no further need to recruit neutrophils and monocytes.
Infection of CBA mice with the pathogenic RacL11 EHV-1 strain results
in primarily a lymphocytic and neutrophilic interstitial pneumonia
in contrast to the lung eosinophilia observed following infection of
the mouse with respiratory syncytial virus (RSV) (25, 33, 34,
38). The involvement of eosinophils following RSV infection of
the lung is thought to be closely linked to the production of
eosinophilic factors including RANTES and IL-5 (25, 38).
Although RANTES transcripts are produced at slightly higher levels in
RacL11-infected lungs than in KyA-infected lungs (Fig. 4), no
appreciable differences between the levels of IL-5 transcripts were
detected (data not shown).
Previous studies have demonstrated the induction of MIP-1
, MIP-1
,
and MIP-2 expression by stimulation with TNF-
(8, 19,
20). The results in Fig. 4A are in agreement with this reported
observation and show a concurrent upregulation of TNF-
transcripts
on day 3 postinfection in RacL11-infected mice. Taken together, the
results presented here suggest that proinflammatory MIP-1
, MIP-1
,
and MIP-2 are produced at high levels in response to RacL11 by day 3 postinfection and are downregulated by day 5, when the inflammatory
infiltration and resulting tissue damage are severe.
A clear distinction between the levels of virus in the lungs and the
immunopathological destruction observed was shown recently in a study
of herpes simplex virus type 1 (HSV-1) pneumonia in mice
(2). It was shown that inhibition of the inducible form of
nitric oxide synthetase (NOS2) reduced the immunopathology associated
with pneumonia to the extent that mice survived normally lethal doses.
Interestingly, the levels of HSV-1 recovered from infected lungs in
mice receiving the specific inhibitor were significantly greater than
those from untreated controls. Therefore, NOS2 and nitric oxide itself
appear to be important for HSV-1 clearance from the lung but also have
a detrimental effect, inducing the immunopathological changes
associated with lethal pneumonia. It is likely that the response to
EHV-1 in the lung walks the fine line between elimination of infection
and induction of damaging pathology.
If the difference between the responses to KyA and RacL11 cannot be
explained by differences in viral load in the lung, then RacL11 must
encode a protein(s) important in eliciting the immunopathology observed. Sequence analysis of EHV-1 KyA revealed a number of deletions within open reading frames (ORFs) in the viral genome. Deletions within the unique short segment of the genome include the viral envelope glycoproteins gI and gE, an ORF encoding a 10-kDa
protein (21), and a large deletion in the EUS4 ORF
(15). Deletions within the unique long (UL) region of the
genome include an internal in-frame deletion within the EICP0 gene
(9), a 1,283-bp deletion near the UL terminus (46,
47), and a 1,207-bp deletion located 5' to the glycoprotein C ORF
(29). Presently, it is not clear which of these gene
products is associated with the immunopathology observed in mice or
equines. However, deletion of the ORFs encoding gI and gE rendered a
pathogenic strain of EHV-1 avirulent in horses, implicating these two
viral glycoproteins as potential mediators of immunopathology
(27). The fact that EHV-1 RacL11 is cleared from the lungs
as efficiently as KyA suggests that one or more of these viral
components is associated with the induction of these proinflammatory
mediators associated with EHV-1 pathogenicity. Studies to address this
question are in progress.
 |
ACKNOWLEDGMENTS |
We thank Suzanne Zavecz, Marie Bruce, and Deborah Dempsey for
excellent technical assistance and H. van der Heyde for critical reading of the manuscript.
This study was supported in part by research grant AI 22001 (D.J.O.)
and by funds made available through Boehringer Ingelheim Vetmedica
GmbH, Ingleheim, Germany.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130. Phone: (318) 675-5750. Fax: (318) 675-5764. E-mail: docall{at}lsuhsc.edu.
 |
REFERENCES |
| 1.
|
Adams, E. M.,
J. Kirkley,
G. Eidelman,
J. Dohlman, and P. H. Plotz.
1997.
The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases.
Proc. Assoc. Am. Physicians
109:275-285[Medline].
|
| 2.
|
Adler, H.,
J. L. Beland,
N. C. Del-Pan,
L. Kobzik,
J. P. Brewer,
T. R. Martin, and I. J. Rimm.
1997.
Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2).
J. Exp. Med.
185:1533-1540[Abstract/Free Full Text].
|
| 3.
|
Afford, S. C.,
N. C. Fisher,
D. A. Neil,
J. Fear,
P. Brun,
S. G. Hubscher, and D. H. Adams.
1998.
Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis.
J. Pathol.
186:82-89[CrossRef][Medline].
|
| 4.
|
Alber, D. G.,
J. Greensill,
R. A. Killington, and A. Stokes.
1995.
Role of T-cells, virus neutralizing antibodies and complemented-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice.
Res. Vet. Sci.
59:205-213[CrossRef][Medline].
|
| 5.
|
Allen, G. P., and J. T. Bryans.
1986.
Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.
Prog. Vet. Microbiol. Immunol.
2:78-144[Medline].
|
| 6.
|
Allen, G. P.,
J. H. Kydd,
J. D. Slater, and K. C. Smith.
1998.
Advances in understanding of the pathogenesis, epidemiology and immunological control of equine herpesvirus abortion, p. 129-146.
In
U. Wernery, J. F. Wade, J. A. Mumford, and O.-R. Kaaden (ed.), Proceedings of the Eighth International Conference of Equine Infectious Diseases. R & W Publishers, Newmarket, United Kingdom.
|
| 7.
|
Awan, A. R.,
Y. C. Chong, and H. J. Field.
1990.
The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection.
J. Gen. Virol.
71:1131-1140[Abstract/Free Full Text].
|
| 8.
|
Bliss, S. K.,
A. J. Marshall,
Y. Zhang, and E. Y. Denkers.
1999.
Human polymorphonuclear leukocytes produce IL-12, TNF-alpha, and the chemokines macrophage-inflammatory protein-1 alpha and -1 beta in response to Toxoplasma gondii antigens.
J. Immunol.
162:7369-7375[Abstract/Free Full Text].
|
| 9.
|
Bowles, D. E.,
V. R. Holden,
Y. Zhao, and D. J. O'Callaghan.
1997.
The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters.
J. Virol.
71:4904-4914[Abstract].
|
| 10.
|
Bryans, J. T., and G. P. Allen.
1969.
On immunity to disease caused by equine herpesvirus-1.
Am. Vet. Med. Assoc.
155:294-300.
|
| 11.
|
Burki, F.,
W. Rossmanith,
N. Nowotny,
C. Pallan,
K. Mostl, and H. Lussy.
1990.
Viremia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses.
Vet. Q.
12:80-86[Medline].
|
| 12.
|
Burrows, R.,
D. Goodridge, and M. S. Denyer.
1984.
Trials of an inactivated equid herpesvirus-1 vaccine: challenge with a subtype-1 virus.
Vet. Res.
114:369-374.
|
| 13.
|
Carrol, C. L., and H. A. Westbury.
1985.
Isolation of equine herpesvirus type 1 from the brain of a horse affected with paresis.
Aust. Vet. J.
62:345-346[Medline].
|
| 14.
|
Colle, C. F., III,
C. C. Flowers, and D. J. O'Callaghan.
1992.
Open reading frames encoding a protein kinase, homolog of glycoprotein gX of pseudorabies virus, and a novel glycoprotein map within the unique short segment of equine herpesvirus type 1.
Virology
188:545-557[CrossRef][Medline].
|
| 15.
|
Colle, C. F., III, and D. J. O'Callaghan.
1995.
Transcriptional analyses of the unique short segment of EHV-1 strain Kentucky A.
Virus Genes
9:257-268[CrossRef][Medline].
|
| 16.
|
Davatelis, G.,
P. Tekamp-Olson, and S. D. Wolpe.
1988.
Cloning and characterization of cDNA for murine macrophage inflammatory protein (MIP): a novel monokine with inflammatory and chemokinetic properties.
J. Exp. Med.
167:1939-1944[Abstract/Free Full Text].
|
| 17.
|
Davatelis, G.,
S. D. Wolpe,
B. Sherry,
J. M. Dayer,
R. Chicheportiche, and A. Cerami.
1989.
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen.
Science
243:1066-1068[Abstract/Free Full Text].
|
| 18.
|
Driscoll, K. E.
1994.
Macrophage inflammatory proteins: biology and role in pulmonary inflammation.
Exp. Lung Res.
20:473-490[Medline].
|
| 19.
|
Driscoll, K. E.,
D. G. Hassenbein, and J. Carter.
1993.
Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung after mineral dust exposures.
Am. J. Respir. Cell. Mol. Biol.
8:311-328.
|
| 20.
|
Dudley, D. J.,
S. Spencer,
S. Edwin, and M. D. Mitchell.
1995.
Regulation of human decidual cell macrophage inflammatory protein-1 alpha (MIP-1 ) production by inflammatory cytokines.
Am. J. Reprod. Immunol.
34:231-235.
|
| 21.
|
Flowers, C. C., and D. J. O'Callaghan.
1992.
The equine herpesvirus type 1 (EHV-1) homolog of herpes simplex virus type 1 US9 and the nature of a major deletion within the unique short segment of the EHV-1 KyA strain genome.
Virology
190:307-315[CrossRef][Medline].
|
| 22.
|
Hannant, D.,
D. M. Jessett,
T. O'Neill,
C. A. Dolby,
R. F. Cook, and J. A. Mumford.
1993.
Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain.
Res. Vet. Sci.
54:299-305[Medline].
|
| 23.
|
Huang, S.,
J. D. Paulauskis,
J. J. Godleski, and L. Kobzik.
1992.
Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation.
Am. J. Pathol.
141:981-988[Abstract].
|
| 24.
|
Jackson, T. A., and J. W. Kendrick.
1971.
Paralysis of horses associated with equine herpesvirus 1 infection.
J. Am. Vet. Med. Assoc.
158:1351-1357[Medline].
|
| 25.
|
Johnson, T. R.,
J. E. Johnson,
S. R. Roberts,
G. W. Wertz,
R. A. Parker, and B. S. Graham.
1998.
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge.
J. Virol.
72:2871-2880[Abstract/Free Full Text].
|
| 26.
|
Johnston, C. J.,
J. N. Finkelstein,
R. Gelein, and G. Oberdorster.
1998.
Pulmonary cytokine and chemokine mRNA levels after inhalation of lipopolysaccharide in C57BL/6 mice.
Toxicol. Sci.
46:300-307[Abstract/Free Full Text].
|
| 27.
|
Matsumura, T.,
T. Kondo,
S. Sugita,
A. M. Damiani,
D. J. O'Callaghan, and H. Imagawa.
1998.
An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses.
Virology
242:68-79[CrossRef][Medline].
|
| 28.
|
Matsumura, T.,
D. J. O'Callaghan,
T. Kondo, and M. Kamada.
1996.
Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses.
Vet. Microbiol.
48:353-365[CrossRef][Medline].
|
| 29.
|
Matsumura, T.,
R. H. Smith, and D. J. O'Callaghan.
1993.
DNA sequence and transcriptional analyses of the region of the equine herpesvirus type 1 Kentucky A strain genome encoding glycoprotein C.
Virology
193:910-923[CrossRef][Medline].
|
| 30.
|
Meyer, H.,
P. Thein, and P. Hubert.
1987.
Characterization of two equine herpesvirus (EHV) isolates associated with neurological disorders in horses.
Zentbl. Vetmed. Reihe B
34:545-548.
|
| 31.
|
Mumford, J. A.,
D. A. Hannant,
D. M. Jessett,
T. O'Neill,
K. C. Smith, and E. N. Ostlund.
1995.
Abortogenic and neurological disease caused by infection with equid herpesvirus-1, p. 261-275.
In
H. Nakajima, and W. Plowright (ed.), Proceedings of the 7th International Conference of Equine Infectious Diseases. R & W Publishers, Newmarket, United Kingdom.
|
| 32.
|
O'Callaghan, D. J., and N. Osterrieder.
1999.
Equine herpesviruses, p. 508-515.
In
R. Webster, and A. Granoff (ed.), Encyclopedia of virology. Academic Press Ltd., London, United Kingdom.
|
| 33.
|
Olszewska-Pazdrak, B.,
A. Casola,
T. Saito,
R. Alam,
S. E. Crowe,
F. Mei,
P. L. Ogra, and R. P. Garofalo.
1998.
Cell-specific expression of RANTES, MCP-1, and MIP-1 by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus.
J. Virol.
72:4756-4764[Abstract/Free Full Text].
|
| 34.
|
Olszewska-Pazdrak, B.,
K. Pazdrak,
P. L. Ogra, and R. P. Garofalo.
1998.
Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism.
J. Immunol.
160:4889-4895[Abstract/Free Full Text].
|
| 35.
|
Osterrieder, N.,
A. Neubauer,
C. Brandmuller,
O.-R. Kaaden, and D. J. O'Callaghan.
1996.
The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence.
Virology
226:243-252[CrossRef][Medline].
|
| 36.
|
Osterrieder, N.,
A. Neubauer,
C. Brandmuller,
O.-R. Kaaden, and D. J. O'Callaghan.
1998.
The equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamin is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection.
J. Virol.
72:9806-9817[Abstract/Free Full Text].
|
| 37.
|
Perdue, M. L.,
M. C. Kemp,
C. C. Randall, and D. J. O'Callaghan.
1974.
Studies of the molecular anatomy of the L-M strain of equine herpesvirus type 1: protein of the nucleocapsid and intact virion.
Virology
59:201-216[CrossRef][Medline].
|
| 38.
|
Saito, T.,
R. W. Deskin,
A. Casola,
H. Haeberle,
B. Olszewska,
P. B. Ernst,
R. Alam,
P. L. Ogra, and R. Garofalo.
1997.
Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells.
J. Infect. Dis.
175:497-504[Medline].
|
| 39.
|
Saukkonen, K.,
S. Sande, and C. Cioffe.
1990.
The role of cytokines in the generation of inflammation and tissue damage in experimental gram positive meningitis.
J. Exp. Med.
171:439-448[Abstract/Free Full Text].
|
| 40.
|
Scott, J. C.,
S. K. Dutta, and A. C. Myrup.
1983.
In vivo harboring of equine herpesvirus-1 in leukocyte populations and subpopulations and their quantitation from experimentally infected ponies.
Am. J. Vet. Res.
44:1344-1348[Medline].
|
| 41.
|
Smith, P. M.,
Y. Zhang,
S. R. Jennings, and D. J. O'Callaghan.
1998.
Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.
J. Virol.
72:5366-5372[Abstract/Free Full Text].
|
| 42.
|
Su, Y. H.,
X. T. Yan,
J. E. Oakes, and R. N. Lausch.
1996.
Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.
J. Virol.
70:1277-1281[Abstract].
|
| 43.
|
Wang, J. M.,
B. Sherry,
J. M. Fivash,
D. J. Kelvin, and J. J. Oppenheim.
1993.
Human recombinant macrophage inflammatory protein-1 and and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes.
J. Immunol.
150:3022-3028[Abstract].
|
| 44.
|
Wolpe, S. D.,
B. Sherry,
D. Juers,
G. Davatelis,
R. W. Yurt, and A. Cerami.
1989.
Identification and characterization of macrophage inflammatory protein 2.
Proc. Natl. Acad. Sci. USA
86:612-616[Abstract/Free Full Text].
|
| 45.
|
Xing, Z.,
M. Jordana,
H. Kirpalani,
K. E. Driscoll,
T. J. Schall, and J. Gauldie.
1994.
Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6, but not RANTES or transforming growth factor beta 1 mRNA expression in acute lung inflammation.
Am. J. Respir. Cell. Mol. Biol.
10:148-153[Abstract].
|
| 46.
|
Yalamanchili, R. R., and D. J. O'Callaghan.
1990.
Sequence and organization of the genomic termini of equine herpesvirus type 1.
Virus Res.
15:149-162[CrossRef][Medline].
|
| 47.
|
Yalamanchili, R. R., and D. J. O'Callaghan.
1990.
Equine herpesvirus sequence near the left terminus codes for two open reading frames.
Virus Res.
18:109-116.
|
| 48.
|
Zhang, Y.,
P. M. Smith,
S. R. Jennings, and D. J. O'Callaghan.
2000.
Quantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D.
Virology
268:482-492[CrossRef][Medline].
|
| 49.
|
Zhang, Y.,
P. M. Smith,
E. B. Tarbet,
N. Osterrieder,
S. R. Jennings, and D. J. O'Callaghan.
1998.
Protective immunity against equine herpesvirus type 1 (EHV-1) infection in mice induced by recombinant EHV-1 gD.
Virus Res.
56:11-24[CrossRef][Medline].
|
Journal of Virology, November 2000, p. 10034-10040, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Van de Walle, G. R., Sakamoto, K., Osterrieder, N.
(2008). CCL3 and Viral Chemokine-Binding Protein gG Modulate Pulmonary Inflammation and Virus Replication during Equine Herpesvirus 1 Infection. J. Virol.
82: 1714-1722
[Abstract]
[Full Text]
-
Van de Walle, G. R., May, M. L., Sukhumavasi, W., von Einem, J., Osterrieder, N.
(2007). Herpesvirus Chemokine-Binding Glycoprotein G (gG) Efficiently Inhibits Neutrophil Chemotaxis In Vitro and In Vivo. J. Immunol.
179: 4161-4169
[Abstract]
[Full Text]
-
Smith, P. M., Kahan, S. M., Rorex, C. B., von Einem, J., Osterrieder, N., O'Callaghan, D. J.
(2005). Expression of the Full-Length Form of gp2 of Equine Herpesvirus 1 (EHV-1) Completely Restores Respiratory Virulence to the Attenuated EHV-1 Strain KyA in CBA Mice. J. Virol.
79: 5105-5115
[Abstract]
[Full Text]